๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

โœ Scribed by Ramesh K. Ramanathan; Sakkaraiappan Ramalingam; Merrill J. Egorin; Chandra P. Belani; Douglas M. Potter; Marwan Fakih; Laura L. Jung; Sandra Strychor; Samuel A. Jacobs; David M. Friedland; Dong M. Shin; Gurkamal S. Chatta; Susan Tutchko; William C. Zamboni

Publisher
Springer
Year
2004
Tongue
English
Weight
227 KB
Volume
55
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I trial of weekly docetaxel and ge
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
โœ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem

Phase I clinical trial of weekly combine
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
โœ Jacob Lokich ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P